Isabella C. Glitza

Roswell Park Comprehensive Cancer Center — United States

Medicine · Health Sciences

38h-index13.9kcitations316works0.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(213), Immunotherapy and Immune Responses(132), Immune cells in cancer(99), Brain Metastases and Treatment(45), CAR-T cell therapy research(32)

Publications315 total

Adjuvant therapy in mucosal melanoma: a single-center experience and review of the literature
Melanoma Research·2025
Editor’s Note: Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
Cancer Discovery·2025Open Access
INSURANCE APPROVAL TIMELINE FOR PROTON CRANIOSPINAL IRRADIATION FOR LEPTOMENINGEAL DISEASE AT AN ACADEMIC CANCER CENTER IN THE UNITED STATES
International Journal of Particle Therapy·2025Open Access
569 A phase 1/2 study of KSQ-004EX: autologous tumor infiltrating lymphocytes, engineered to inactivate genes encoding SOCS1 and regnase-1, in patients with select advanced solid tumors
Regular and Young Investigator Award Abstracts·2025Open Access
DDEL-15. EnTrega CSF circulation and drug delivery system improves drug distribution in brain parenchyma
Neuro-Oncology·2025Open Access
The Role of Adjuvant Primary Site Radiotherapy for Patients with Cutaneous Melanoma Microsatellitosis
International Journal of Radiation Oncology*Biology*Physics·2025
Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma
OncoImmunology·2025· 1 citedOpen Access
OGCT-03 PHASE I/IB STUDY OF CONCURRENT INTRAVENOUS (IV) AND INTRATHECAL (IT) NIVOLUMAB (N) AND RELATLIMAB (R) FOR METASTATIC MELANOMA (MM) PATIENTS (PTS) WITH LEPTOMENINGEAL DISEASE (LMD)
Neuro-Oncology Advances·2025Open Access
SRDA-01 DYNAMIC CONTROL OF CEREBROSPINAL FLUID FLOW TO ACHIEVE PERSONALIZED DRUG DELIVERY IN THE CENTRAL NERVOUS SYSTEM
Neuro-Oncology Advances·2025Open Access
Abstract 1784: Dynamic control of cerebrospinal fluid to achieve personalized drug delivery in the central nervous system
Cancer Research·2025
Trial in Progress: Ph I/IIa dose finding study of Triplet regimen of Relatlimab (RELA) Ipilimumab (IPI) and NIvolumab (NIVO) in first line TherapY of metastatic melanoma (MM) (TRINITY)
EJC Skin Cancer·2025Open Access
Expanded accrual and analysis of neoadjuvant plus adjuvant (neo+adj) dabrafenib (D) + trametinib (T) in patients (pts) with resectable stage (stg) III/IV melanoma
EJC Skin Cancer·2025Open Access
660 A phase 1/2 study of KSQ-001EX: an autologous tumor-infiltrating lymphocyte therapy engineered to inactivate the<i>SOCS1</i>gene in patients with select advanced solid tumors
Regular and Young Investigator Award Abstracts·2024Open Access
1256 Delineating the role of the microbiome and tumor microenvironment interactions driving mucosal melanoma response and resistance to immune checkpoint inhibitor treatment
Regular and Young Investigator Award Abstracts·2024Open Access
Hypofractionated Radiation Therapy for Unresectable or Bulky Metastatic Melanoma
International Journal of Radiation Oncology*Biology*Physics·2024· 1 citedOpen Access
71MO Clinical and biomarker analyses of intratumoral CD40 agonist sotigalimab in combination with pembrolizumab in metastatic melanoma: A phase I/II trial
Annals of Oncology·2024Open Access
Supplementary Figure S7 from Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity
2024Open Access
Supplementary Figure S4 from Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity
2024Open Access
Supplementary Table S8 from Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity
2024Open Access
Supplementary Figure S16 from Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity
2024Open Access
page 1 of 16Next →

Frequent Co-authors

Michael A. Davies(32), Adi Diab(24), Hussein A. Tawbi(24), Rodabe N. Amaria(23), Sapna P. Patel(21), Michael T. Tetzlaff(19), Jennifer A. Wargo(19), Scott E. Woodman(15), Jeffrey E. Gershenwald(15), Patrick Hwu(14), Jennifer L. McQuade(12), Michael K. Wong(12), Lauren E. Haydu(11), Alexander J. Lazar(11), Wen-Jen Hwu(11), Vancheswaran Gopalakrishnan(10), Alexandre Reuben(10), Elizabeth M. Burton(10), Padmanee Sharma(10), James P. Allison(10)